Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket

Shares of Cardlytics, Inc. (NASDAQ:CDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter earnings.

Cardlytics posted adjusted earnings of 14 cents per share, beating market estimates of 12 cents per share, according to data from Benzinga Pro. The company said it sees first-quarter revenue of $70 million to $73 million, versus expectations of $66.46 million.

Cardlytics shares jumped 36.6% to $11.18 in pre-market trading

Here are some other stocks moving in pre-market trading.

Gainers

• Fisker Inc. (NYSE:FSR) shares rose 31.3% to $0.2034 in pre-market trading. Fisker shares dipped around 52% on Thursday following a Wall Street Journal report suggesting the company is preparing for a possible bankruptcy filing.
• Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) rose 26.9% to $309.13 in pre-market trading after the company announced FDA approval of Rezdiffra for the treatment of patients with noncirrhotic NASH with moderate to advanced liver fibrosis.
• 2seventy bio, Inc. (NASDAQ:TSVT) shares gained 18.7% to $4.70 in pre-market trading. On March 5, 2seventy bio posted downbeat quarterly results.
• American Vanguard Corporation (NYSE:AVD) climbed 16% to $12.28 in pre-market trading following fourth-quarter financial results.
• Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) gained 14.4% to $1.99 in pre-market trading.
• Telesis Bio, Inc. (NASDAQ:TBIO) gained 11.6% to $0.5740 in pre-market trading. On Feb. 26, Telesis Bio announced select preliminary fourth-quarter financial results.
• Brera Holdings PLC (NASDAQ:BREA) shares rose 11% to $1.61 in pre-market trading after falling 6% on Thursday.
• Aquestive Therapeutics, Inc. (NASDAQ:AQST) shares gained 8.2% to $5.68 in pre-market trading. Aquestive Therapeutics said Anaphylm met all predefined primary and secondary pharmacokinetic endpoints.
• Better Therapeutics, Inc (NASDAQ:BTTX) rose 7.7% to $0.0377 in pre-market trading. Better Therapeutics shares dipped 83% on Thursday after the company announced that it will seek strategic alternatives and will be delisted from the Nasdaq.

Losers

• Kopin Corporation (NASDAQ:KOPN) fell 14.6% to $1.87 pre-market trading after reporting weaker-than-expected fourth-quarter results.
• Smartsheet Inc. (NASDAQ:SMAR) fell 11.8% to $35.56 in pre-market trading after the company reported fourth-quarter financial results and issued FY25 revenue guidance below estimates.
• Adobe Inc. (NASDAQ:ADBE) dipped 11.3% to $505.88 in pre-market trading. Adobe reported better-than-expected results for its first quarter but issued weak revenue guidance for the current quarter.
• Psyence Biomedical Ltd. (NASDAQ:PBM) fell 10.6% to $1.42 pre-market trading. Psyence Biomedical shares jumped 53% on Thursday after the Indiana legislature sent a bill that includes funding for psilocybin clinical research trials to the governor.
• Presto Automation Inc. (NASDAQ:PRST) fell 9.7% to $0.2720 in pre-market trading after surging 34% on Thursday. The company announced the pricing of a $1.2 million registered direct offering of 4.8 million shares of common stock at $0.25 per share.
• Kuke Music Holding Limited (NYSE:KUKE) declined 9.1% to $2.26 in pre-market trading after gaining 5% on Thursday.
• Alternus Clean Energy Inc (NASDAQ:ALCE) shares tumbled 8.7% to $0.4265 in pre-market trading.
• PagerDuty, Inc. (NYSE:PD) shares fell 8.2% to $21.06 in pre-market trading after the company reported fourth-quarter financial results and issued FY25 guidance below estimates.
• Blink Charging Co. (NASDAQ:BLNK) shares fell 7.6% to $3.17 in pre-market trading following fourth-quarter financial results.
• Ulta Beauty, Inc. (NASDAQ:ULTA) shares tumbled 6.6% to $ 527.99 after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. The company's board of directors approved a new share repurchase authorization of $2.0 billion.

Now Read This: Hibbett Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call